The Smpc
Found 9 free book(s)London, 20 November 2008 - European Commission
ec.europa.euPage 3 of 29 SUMMARY OF PRODUCT CHARACTERISTICS: Principles of presenting information - The SmPC should be worded in clear and concise language. - Each section of the SmPC should first deal with those issues that apply to the core population for
Champix, INN Varenicline tartrate
www.ema.europa.euIAIN/0073 C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation 21/09/2018 SmPC and PL T/0071 Transfer of Marketing Authorisation
EMCREM CREAM (White soft paraffin 15.0% w/w, Liquid ...
www.mhra.gov.ukPAR Emcrem Cream PL 19876/0013 2 EMCREM CREAM (White soft paraffin 15% w/w, Liquid paraffin 6% w/w) PL 19876/0013 LAY SUMMARY On 16 March 2011, the Medicines and Healthcare products Regulatory Agency
CYCLIZINE HYDROCHLORIDE 50 MG TABLETS PL …
www.mhra.gov.ukUKPAR Cyclizine Hydrochloride 50 mg Tablets PL 20117/0216 2 CYCLIZINE HYDROCHLORIDE 50 MG TABLETS PL 20117/0216 LAY SUMMARY On 3rd October 2012, the MHRA granted Morningside Healthcare Limited a Marketing Authorisation (licence) for Cyclizine Hydrochloride 50 mg Tablets.
osoba' - PLIVA BiH
www.pliva.baSAZETAK OPISA SVOJSTAVA LIJEKA 1. NAZIV GOTOVOG LIJEKA DINAMICO 50 mg filmom obloZena tableta 100 mg filmom obloZena tableta slldenafil 2. ]O/ALITATIVNI I IOANTITATIVNI SASTAV 1 ftrmom obro?ena tabre od 50 mg naii70,240mg sitdenafira u obriku citrata Eto odgovara 50 mg sildenafila 1 filmom obloZena tableta od 100 mg sadrZi 140,480mg sildenafila u obliku citrata Sto odgovara 100
High Current Density Surface Mount Schottky Barrier Rectifiers
www.vishay.comLegal Disclaimer Notice www.vishay.com Vishay Revision: 08-Feb-17 1 Document Number: 91000 Disclaimer ALL PRODUCT, PRODUCT SPECIFICATIONS AND DATA ARE SUBJECT TO CHANGE WITHOUT NOTICE TO IMPROVE
High Current Density Surface Mount Trench MOS Barrier ...
www.vishay.comLegal Disclaimer Notice www.vishay.com Vishay Revision: 08-Feb-17 1 Document Number: 91000 Disclaimer ALL PRODUCT, PRODUCT SPECIFICATIONS AND DATA ARE SUBJECT TO CHANGE WITHOUT NOTICE TO IMPROVE
New MHRA recommendations on simvastatin interactions ...
www.wales.nhs.ukABHB Medicine Management team contact details at http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=62124 September 2012 Page 1 of 2 New MHRA recommendations on ...
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euTruxima should be administered under the close supervision of an experienced healthcare professional, and in an environment where full resuscitation facilities are immediately available (see